Survival of Patients With Neuroendocrine Carcinoma of the Colon and Rectum

摘要: BACKGROUND High-grade neuroendocrine carcinoma is a rare colorectal pathology described in case series. The role of surgery this disease has been questioned. OBJECTIVE purpose work was to describe the incidence, management, and outcomes comparison with high-grade adenocarcinoma. DESIGN This retrospective, population-based research study. SETTINGS Survey Epidemiology End Results database used. PATIENTS A total 1367 patients (distinguishing small-cell non-small-cell subtypes) 72,533 adenocarcinoma diagnosed between 2000 2011 were included INTERVENTIONS Resection primary tumor main intervention. MAIN OUTCOME MEASURES Median overall 5-year relative survival measured. Trends expressed as annual percent change incidence survival. RESULTS rate increased for (annual change, +2.2%; p =0.035) decreased -3.1%; < 0.00001) during study period. Relative at 5 years 16.3% 57.4%, 56.4%, 26.3%, 3.0% stages I, II, III, IV cancer. Small-cell tumors had worse (10% versus 19% non-small cell). There no improvement -1.1%; =0.06) contrast +0.7%; 0.00001). Patients localized better (median, 21 months) than without (6 months; log-rank, 0.0001), whereas those did not (18 14 = 0.95). Prognosis resected an increasing number metastatic lymph nodes. LIMITATIONS Histology grade assignments centrally verified. Data on chemotherapy use, patient performance status, comorbidities unavailable. CONCLUSIONS Neuroendocrine benefit from advances prevention treatment over past decade. Relatively poor early stage warrants studies adjuvant systemic therapy. differences carcinomas indicate need histology-specific management.